IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v18y2021i16p8242-d607935.html
   My bibliography  Save this article

Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond

Author

Listed:
  • Michał Nowicki

    (Department of Nephrology, Hypertension, and Kidney Transplantation, Medical University of Łódź, 90-145 Łódź, Łódzkie, Poland)

  • Stanisława Bazan-Socha

    (Department of Internal Medicine, Jagiellonian University Medical College, 30-688 Kraków, Małopolskie, Poland)

  • Mariusz Kłopotowski

    (Department of Interventional Cardiology and Angiology, Institute of Cardiology, 04-628 Warsaw, Mazowieckie, Poland)

  • Beata Błażejewska-Hyżorek

    (2nd Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Mazowieckie, Poland)

  • Mariusz Kusztal

    (Department of Nephrology and Transplantation Medicine, Wrocław Medical University, 50-556 Wrocław, Dolnośląskie, Poland)

  • Krzysztof Pawlaczyk

    (Department of Nephrology, University Hospital of Karol Marcinkowski in Zielona Góra, 65-046 Zielona Góra, Lubuskie, Poland
    Department of Nephrology, Transplantology, and Internal Diseases, Poznań University of Medical Sciences, 60-355 Poznań, Wielkopolskie, Poland)

  • Jarosław Sławek

    (Division of Neurological and Psychiatric Nursing, Institute of Nursing and Midwifery, Medical University of Gdańsk, 80-462 Gdańsk, Pomorskie, Poland)

  • Andrzej Oko

    (Department of Nephrology, Transplantology, and Internal Diseases, Poznań University of Medical Sciences, 60-355 Poznań, Wielkopolskie, Poland)

  • Zofia Oko-Sarnowska

    (Department of Cardiology, Poznań University of Medical Sciences, 60-355 Poznań, Wielkopolskie, Poland
    Polish Fabry Disease Collaborative Group are listed in acknowledgments.)

Abstract

Current therapy for Anderson–Fabry disease in Poland includes hospital or clinic-based intravenous enzyme replacement therapy with recombinant agalsidase alpha or beta, or oral pharmacological chaperone therapy with migalastat. Some countries around the world offer such treatment to patients in the comfort of their own homes. The 2020–2021 COVID-19 pandemic has pushed global healthcare providers to evolve their services so as to minimize the risk of COVID-19 exposure to both patients and providers; this has led to advances in telemedicine services and the increasing availability of at-home treatment for various procedures including parenteral drug administration. A total of 80% of surveyed Anderson–Fabry disease patients in Poland would prefer home-based treatment, which would be a safe and convenient alternative to clinic-based treatment if patient selection is based on our proposed algorithm. Our recommendations for home-based treatments appear feasible for the long term care of Anderson–Fabry disease patients during the COVID-19 pandemic and beyond. This may also serve as a basis for home-based treatment programs in other rare and ultra-rare genetic diseases.

Suggested Citation

  • Michał Nowicki & Stanisława Bazan-Socha & Mariusz Kłopotowski & Beata Błażejewska-Hyżorek & Mariusz Kusztal & Krzysztof Pawlaczyk & Jarosław Sławek & Andrzej Oko & Zofia Oko-Sarnowska, 2021. "Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond," IJERPH, MDPI, vol. 18(16), pages 1-12, August.
    • Handle: RePEc:gam:jijerp:v:18:y:2021:i:16:p:8242-:d:607935
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/18/16/8242/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/18/16/8242/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:16:p:8242-:d:607935. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.